| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44733 | ORGANON SUB MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jan, 2026
(2 years from now) | |
Bridion is owned by Organon Sub Merck.
Bridion contains Sugammadex Sodium.
Bridion has a total of 1 drug patent out of which 0 drug patents have expired.
Bridion was authorised for market use on 15 December, 2015.
Bridion is available in solution;intravenous dosage forms.
Bridion can be used as reversal of drug-induced neuromuscular block.
The generics of Bridion are possible to be released after 27 January, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 25, 2024 |
| M (M) | Jan 22, 2024 |
Drugs and Companies using SUGAMMADEX SODIUM ingredient
Market Authorisation Date: 15 December, 2015
Treatment: Reversal of drug-induced neuromuscular block
Dosage: SOLUTION;INTRAVENOUS
BRIDION family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic